Our Current Trials

Condition Trial Name Sponsor
Solid Tumors 1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors Boehringer Ingelheim
Solid Tumors 1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors Mirati Therapeutics, Inc.
Rectal Cancer 19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma Memorial Sloan Kettering Cancer Center
Breast Cancer ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer Gilead Sciences
Breast Cancer ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer Gilead Sciences
Breast Cancer ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer Gilead Sciences, Inc.
Cachexia in Colorectal or Pancreatic Cancer AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy AVEO Pharmaceuticals, Inc.
Solid Tumors BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors Boehringer Ingelheim
Breast Cancer BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy BriaCell Therapeutics Corporation
Biliary Tract Cancer, Pancreatic Cancer Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer Boehringer Ingelheim
Solid Tumor or Lymphoma CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas CStone Pharmaceuticals
Solid Tumors DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors Day One Biopharmaceuticals, Inc.
Breast Cancer DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer AstraZeneca
Breast Cancer ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor Stemline Therapeutics, Inc.
Central Nervous System Cancer F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy Fore Biotherapeutics
Solid Tumors F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors Fore Biotherapeutics
Gastric or Gastroesophageal Junction Cancer GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma AstraZeneca
Head and Neck Squamous Cell Carcinoma GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC Gilead Sciences, Inc.
Non-Small Cell Lung Cancer HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma Lantern Pharma Inc.
Colon or Rectal Cancer KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer Mirati Therapeutics, Inc.
Solid Tumors KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors Mirati Therapeutics Inc.
Colon or Rectal Cancer LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash Lutris Pharma Ltd.
Non-Hodgkin Lymphoma MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa
Solid Tumors PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor Aadi Bioscience, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, or Select B-Cell Malignancies Prelude Therapeutics
ITP, wAIHA, CAD RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias Alpine Immune Sciences, Inc.
Breast Cancer SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression AstraZeneca
Breast Cancer SPI-GCF-104: Same Day Administration of Eflapegrastim to Treat Neutropenia in Patients Being Treated With Neo/Adjuvant Docetaxel Plus Cyclophosphamide Spectrum Pharmaceuticals, Inc.
Multiple Myeloma TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma Takeda Development Center Americas, Inc
Solid Tumors TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study Hoffmann-La Roche
Non-Small Cell Lung Cancer TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer Daiichi Sankyo, Inc.
Ovarian, Fallopian Tube or Primary Peritoneal Cancer ZN-c3-005: Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer K-Group, Beta, Inc.
Cancer Diagnosis [Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients Memorial Sloan Kettering Cancer Center
Various Indications [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine
Solid Tumors [Sample Collection] Collection and Distribution of Biofluids for Research Purposes Bluestar Genomics
Solid Tumors [Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) Exact Sciences Thrive LLC
Various Indications [Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) MT Group
Various Indications [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC.
Solid Tumors [Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening Freenome Holdings Inc.
Solid Tumors eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion Merus N.V.